33 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
”), diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. The sublingual formulation
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
”), diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. The sublingual formulation
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
sublingual spray formulation (collectively, the “Spray Formulations”), diversifying our pipeline of non-opioid pain treatment therapies, while adding
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
dominated by opioid analgesics. Opioid analgesics decrease the perception of pain by stimulating a range of opioid receptors that modulate pain signals … . The most widely used opioid analgesics, including morphine, fentanyl and hydromorphone, act primarily through the activation of mu opioid receptors
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
dominated by opioid analgesics. Opioid analgesics decrease the perception of pain by stimulating a range of opioid receptors that modulate pain signals … . The most widely used opioid analgesics, including morphine, fentanyl and hydromorphone, act primarily through the activation of mu opioid receptors
10-K
b2ftdkem ex
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
69woznuy
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
9nhvlg2l
21 Mar 24
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
9:00am
8-K
EX-99.1
sq0easf7 ab
18 Mar 24
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
4:05pm
8-K
EX-99.1
5dwyap
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-99.1
6rp54m3aky ize1
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-99.2
bim64s58ywu9v
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
mc3 ig3meiumxnsva5
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
mmize
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
arcknwx5h0ptiwi 4c6
12 Feb 24
Free writing prospectus
8:09am
FWP
ru59hsoq7x
6 Feb 24
Free writing prospectus
8:43pm
FWP
ypv6b8tqg7hd4
31 Jan 24
Free writing prospectus
4:16pm